Trials / Completed
CompletedNCT00061425
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | radiolabeled epratuzumab |
Timeline
- Start date
- 2000-08-01
- Primary completion
- 2007-11-01
- First posted
- 2003-05-28
- Last updated
- 2021-08-19
Source: ClinicalTrials.gov record NCT00061425. Inclusion in this directory is not an endorsement.